Skip to main content
SciBX
Feature Story

Cover Story: CRISPR in the liver

By Amy Donner, Senior Editor

CRISPR in the liver

Despite the fact that the therapeutic utility of CRISPR-based approaches has yet to be demonstrated, venture dollars keep flowing into new companies developing the platform. But proof of concept may come faster than expected as new findings show that a CRIPSR-based compound can correct a mutation in adult mice with genetic liver disease.1

Full Article
  • COVER STORY

    ASCO's honest broker

    ASCO is developing an initiative to facilitate off-label access to targeted cancer therapies. If successful, the system could serve as a model for third-party bodies that could manage early access to experimental therapies.

  • PRODUCT DISCOVERY & DEVELOPMENT

    CAR hits pothole

    Adverse events led to protocol revisions in Sloan Kettering's trial of CD19-targeted CAR T cells. But partner Juno Therapeutics and other CAR players don't think this indicates a class effect.

  • EMERGING COMPANY PROFILE

    Minoryx: Mediating rare metabolism

    Minoryx both identifies novel chaperones and repurposes drugs to treat inherited metabolic diseases.

  • True North: Dynamiting complement

    True North's TNT009 inhibits an upstream target in the classical complement pathway that could lead to greater efficacy and an improved safety profile relative to other complement inhibitors.

  • REGULATION

    Pain politics

    FDA Commissioner Margaret Hamburg responds to critics of the agency's decision to approve Zogenix's Zohydro and warns about consequences for the integrity of science-based regulation.

  • FINANCE

    Ebb & Flow

    Double-dippers defer follow-on plans. Snake eyes for Cytos. Kaleo's royalty deal. Epirus makes it move. Steve Harr's jump to Juno. Also: ALK-Abello; Medivir; ThromboGenics; Topotarget; Zogenix, et al.

FDA Pain

  • COVER STORY

    CRISPR in the liver

    Although the therapeutic utility of CRISPR-based approaches has yet to be demonstrated, venture dollars are flowing into new companies developing the platform. Proof of concept may come faster than expected as new findings show that a CRISPR-based therapeutic can correct a mutation in adult mice with genetic liver disease.

  • TARGETS & MECHANISMS

    Reversing (heart) failure in Friedreich's ataxia

    Heart failure accounts for over half the deaths in patients with Friedreich's ataxia, but there are no therapies for the neurodegenerative disease. Now, a team of French researchers has shown that i.v. frataxin gene therapy could prevent or reverse heart failure in a mouse model of the disease.

  • Leveling cancer with IL-15

    Findings that link high IL-15 levels in tumors with increased local T cell proliferation and favorable patient outcomes position the cytokine as a robust prognostic and complement ongoing efforts to develop IL-15 as a therapeutic in colorectal cancer and other malignancies.

  • Mired in miR-25

    New evidence that miR-25 inhibition can help treat heart failure contradicts earlier results. Although the current study shows that blocking miR-25 restores SERCA2A -- and thus improves cardiac contractility -- discrepancies between the studies need to be resolved before a therapy can be developed.

  • THERAPEUTICS

    This Week in Therapeutics

    Treating type 2 diabetes with a DPP-4 peptide vaccine; inhibiting Nav1.6 to alleviate optic neuritis; using cysteine dietary supplementation to prevent neurotoxicity associated with Huntington's disease; and more...

  • TECHNIQUES

    This Week in Techniques

    Detection of Plasmodium falciparum infection with ultrasound-based separation of red blood cells; blood-based DNA methylation signature for progressive supranuclear palsy and frontotemporal dementia; loss-of-function SMARCA4 mutations associated with small-cell carcinoma of the ovary, hypercalcemia type; and more...

Subscribe Now
Free Trial